{"editorial":{"content_id":"abfbff91-8277-49f3-acc7-1617cad52bd8","slug":"anvisa-20261015-1b6636","content_type":"news","title":"巴西卫生部新血液法规生效，Anvisa发布过渡指南","summary":"巴西卫生部第11.685/2026号部令于2026年9月30日生效，Anvisa发布技术说明指导过渡期，RDC 34/2014继续有效。","body":"巴西卫生部第GM/MS 11.685/2026号部令于2026年9月30日生效，重新定义了国家血液、成分及衍生物系统（SINASAN）范围内血液和血液疗法程序的技术法规体系。巴西国家卫生监督局（Anvisa）就此发布了第75/2026号技术说明，对部令生效及法规过渡期提供指导，并确认第34/2014号董事会决议（RDC 34/2014，血液周期良好规范）继续有效。\n\nAnvisa要求血液疗法服务机构（SH）将操作程序调整至新部令的规定，同时指出两项法规具有互补性，应整合适用。\n\nAnvisa表示，正在完成RDC 34/2014修订的监管影响分析（AIR）。修订过程还涵盖其他血液疗法相关法规，包括涉及血液疗法服务复杂度分级的RDC 151/2001和涉及血液疗法生产信息系统（HEMOPROD）的RDC 149/2001，目标是更新卫生监管框架，并与卫生部确立的最新技​​术指南相协调。初步文本完成后将提交公众咨询，以保障社会参与新规的制定。\n\n为支持卫生监督机构和受监管方度过过渡期，Anvisa对新部令要求与RDC 34/2014现行检查路线图进行了比较研究，并据此创建了“过渡路线图”技术指导工具，用于识别血液疗法服务机构需要更新的主要要点、分歧和调整事项。卫生监督机构应使用新路线图，同时继续使用现行版本的血液疗法服务潜在风险评估方法（MARP-SH），因为血液疗法服务机构的风险分级计算没有变化。\n\n根据技术指南，对更新要求的合规情况应按所涉卫生风险及对血液疗法活动质量和安全的潜在影响进行比例化分析。“过渡路线图2026参考版”已在Anvisa门户网站的血液、组织、细胞、器官和先进治疗产品（检查）区域发布，国家卫生监督系统（SNVS）成员应在新的卫生法规和更新检查工具发布前，使用该路线图支持执法行动。","why_it_matters":null,"cbi_observation":null,"direction_tag":"巴西","primary_category":"科技平台","secondary_topics":["政策","合规","行业趋势","br-health"],"content_level":"编辑整理","event_type":"政策法规","audience_tags":[],"event_location":null,"verification_status":"source_verified","published_at":"2026-10-15T17:01:27.554Z","display_date":"2026-10-15","source_published_at":null,"source_url":"https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/anvisa-orienta-servicos-de-hemoterapia-sobre-transicao-para-nova-portaria-do-ministerio-da-saude","source_name":"Anvisa","source_language":"pt","author_name":"编辑部","risk_level":"low","risk_flags":["compliance_risk","regulatory_uncertainty"],"opportunity_flags":[],"trend_signals":["policy_tightening"]},"intelligence":{"intel_id":"d57f6704-f6b8-457e-8e97-74b746241b65","version":1,"event_type":"政策发布","event_date":"2026-09-30","main_entities":[{"name":"巴西卫生部","role":"发布第GM/MS 11.685/2026号部令，重新定义SINASAN范围内血液和血液疗法程序技术法规体系","type":"government_body","country":"巴西","normalized_name":null},{"name":"Anvisa","role":"发布第75/2026号技术说明，提供过渡期指导并确认RDC 34/2014继续有效","type":"regulator","country":"巴西","normalized_name":null},{"name":"RDC 34/2014","role":"现行血液周期良好规范，继续有效并需与新部令整合适用","type":"policy","country":"巴西","normalized_name":null},{"name":"血液疗法服务机构（SH）","role":"受新部令和Anvisa过渡指南约束，需调整操作程序","type":"sector","country":"巴西","normalized_name":null},{"name":"国家卫生监督系统（SNVS）","role":"成员机构应在更新法规和检查工具发布前使用过渡路线图支持执法行动","type":"government_body","country":"巴西","normalized_name":null}],"main_action":"巴西卫生部新血液法规生效，Anvisa发布技术说明指导过渡并确认RDC 34/2014继续有效","key_numbers":[{"unit":"","label":"部令编号","value":"GM/MS 11.685/2026"},{"unit":"","label":"技术说明编号","value":"75/2026"},{"unit":"","label":"现行良好规范决议编号","value":"RDC 34/2014"},{"unit":"日期","label":"生效日期","value":"2026-09-30"}],"facts":[{"verified":false,"statement":"巴西卫生部第GM/MS 11.685/2026号部令于2026年9月30日生效。","source_excerpt":null},{"verified":false,"statement":"Anvisa发布了第75/2026号技术说明，对部令生效及法规过渡期提供指导。","source_excerpt":null},{"verified":false,"statement":"第75/2026号技术说明确认RDC 34/2014继续有效。","source_excerpt":null},{"verified":false,"statement":"Anvisa要求血液疗法服务机构将操作程序调整至新部令规定，并指出新部令与RDC 34/2014具有互补性，应整合适用。","source_excerpt":null},{"verified":false,"statement":"Anvisa表示正在完成RDC 34/2014修订的监管影响分析，修订过程还涵盖RDC 151/2001和RDC 149/2001。","source_excerpt":null},{"verified":false,"statement":"Anvisa创建了“过渡路线图”技术指导工具，并在其门户网站的血液、组织、细胞、器官和先进治疗产品检查区域发布“过渡路线图2026参考版”。","source_excerpt":null},{"verified":false,"statement":"Anvisa要求继续使用现行版本的血液疗法服务潜在风险评估方法（MARP-SH），因为血液疗法服务机构的风险分级计算没有变化。","source_excerpt":null}],"assessments":[{"statement":"新部令与RDC 34/2014并行适用，血液疗法服务机构在过渡期需同时满足两套要求，短期合规负担可能上升。","confidence":"high","basis_fact_index":null},{"statement":"由于RDC 34/2014等法规修订仍在进行且后续将进入公众咨询，巴西血液疗法监管框架存在阶段性不确定性。","confidence":"medium","basis_fact_index":null},{"statement":"Anvisa发布的过渡路线图有助于降低监管机构与受监管方之间的衔接成本，但实际效果取决于SNVS成员机构的执行。","confidence":"medium","basis_fact_index":null},{"statement":"涉及巴西血液疗法服务、血液成分及衍生物相关业务的企业和机构需关注检查路线图更新及合规调整。","confidence":"medium","basis_fact_index":null}],"actions":[{"target":"user","priority":"high","description":"对照Anvisa“过渡路线图2026参考版”更新内部合规清单，识别与新部令和RDC 34/2014的差距。"},{"target":"both","priority":"high","description":"持续监测RDC 34/2014修订、监管影响分析及公众咨询进展。"},{"target":"user","priority":"normal","description":"将MARP-SH和过渡路线图纳入血液疗法服务机构检查准备与风险分级工作。"},{"target":"system","priority":"normal","description":"面向相关业务团队发布巴西血液法规过渡期监管简报。"}],"affected_audience":["血液疗法服务机构（SH）","卫生监督机构","国家卫生监督系统（SNVS）成员","血液及血液制品相关企业","血液疗法接受者"],"risk_flags":["compliance_risk","regulatory_uncertainty"],"opportunity_flags":[],"trend_signals":["policy_tightening"],"follow_up_needed":true,"follow_up_questions":["RDC 34/2014修订的监管影响分析何时完成并进入公众咨询？","“过渡路线图2026参考版”具体列出的主要更新要点、分歧和调整事项有哪些？","新部令与RDC 34/2014在检查要求上的主要差异是什么？","MARP-SH未来是否会随新法规和检查工具更新而调整？"],"related_topics":["巴西血液法规","SINASAN","Anvisa","RDC 34/2014","血液疗法服务","过渡路线图","HEMOPROD","MARP-SH"],"verification_status":"unverified","confidence_score":0.7,"generated_at":"2026-10-15T17:01:51.145Z"},"meta":{"canonical_url":"https://chinabrazilinsight.com/news/anvisa-20261015-1b6636","api_url":"https://chinabrazilinsight.com/api/public/content/anvisa-20261015-1b6636","markdown_url":"https://chinabrazilinsight.com/api/public/content/anvisa-20261015-1b6636?view=markdown","json_url":"https://chinabrazilinsight.com/api/public/content/anvisa-20261015-1b6636?view=json","last_updated":"2026-10-15T17:01:51.572Z","platform":"China Brazil Insight","platform_url":"https://chinabrazilinsight.com"}}